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Abstract
Introduction: We identified silent liver fibrosis in patients with rheumatoid arthritis (RA) using transient
elastography, and investigated medication that correlated with abnormal liver stiffness measurement (LSM) values.
Methods: We consecutively enrolled 105 patients with RA taking methotrexate over 24 weeks with normal liver
functions and no history of underlying chronic liver disease. Blood tests were performed, and body mass index and
metabolic syndrome were assessed. We checked LSM values, and adopted 5.3 kPa as the cutoff for abnormal LSM
values. The cumulative doses of medications including methotrexate, leflunomide, sulfasalazine,
hydroxychloroquine, prednisolone, meloxicam, and celecoxib were calculated.
Results: The median age of patients (20 men and 85 women) was 52.4 years. The median LSM value was 4.7 kPa and
24 (22.9%) patients had abnormal LSM values. Gamma-glutamyltranspeptidase levels and the cumulative doses of
leflunomide and prednisolone significantly correlated with LSM values (P<0.05). The cumulative dose of leflunomide,
but not methotrexate, was significantly higher in patients with abnormal LSM values than that in patients with normal
LSM values (P = 0.008). When RA patients receiving leflunomide plus methotrexate were classified into two groups
according to the optimal cutoff cumulative dose of leflunomide (19,170 mg), abnormal LSM values were more
frequently identified in patients with high cumulative dose of leflunomide (odds ratio, 12.750; P<0.001).
Conclusions: The cumulative dose of leflunomide was the only independent predictor of abnormal LSM values in
patients with RA who had received methotrexate for more than six months.
Introduction
Rheumatoid arthritis (RA) is characterized by synovial
inflammation in multiple joints and irreversible joint
destruction in the absence of adequate treatment [1,2].
Among various disease-modifying anti-rheumatic drugs
(DMARDs), methotrexate (MTX) has been the most
widely used of these for RA. Moreover, new biological
agents, such as TNF-a blockade and anti-CD20 monoclo-
nal antibody, need a combination treatment with MTX to
reduce the formation of neutralizing antibodies that can
diminish the therapeutic efficacy [3].
Thus, unless patients have systemic conditions that
make MTX treatment unfeasible, such as liver or intersti-
tial lung disease, MTX is usually administered to most RA
patients, either alone or with other DMARDs [4,5].
Despite their potent efficiency, long-term use of MTX can
induce serious adverse events such as hepatitis [6],
although the development of liver cirrhosis due to MTX
use has rarely been reported [7]. Other DMARDs or non-
steroidal anti-inflammatory drugs (NSAIDs) may not be
free from concerns over these adverse effects. Particularly,
leflunomide, which is newly developed and is often used
in combination with MTX, has been reported to signifi-
cantly increase the risk of liver toxicity potentially elevat-
ing liver enzyme levels, or inducing other serious diseases
such as liver fibrosis [8,9].
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From a clinical point of view, physicians may stop
DMARDs or reduce their doses, when the levels of liver
enzymes are highly elevated. However, drug-induced
liver fibrosis can sometimes progress without changes of
enzyme levels, or of structure on ultrasonography. In
these cases, only liver biopsy can detect silent liver
fibrosis, but it cannot be performed in all patients taking
DMARDs, because it is invasive and unethical.
Recently, non-invasive liver stiffness measurement
(LSM) using transient elastography (FibroScan®, Echo-
Sens, Paris, France) was introduced to assess the severity
of liver fibrosis, and to screen the normal population for
identifying people potentially at risk of underlying
chronic liver disease [10-12]. So far, a few studies using
transient elastography have shown a relationship between
MTX use and liver fibrosis, but the association still
remains controversial [13-15]. Furthermore, the com-
bined effect of MTX and other DMARDs on liver fibrosis
has not been described. Hence, in the present study, we
assessed the correlation of the dose of MTX and silent
liver fibrosis and investigated medication that correlated
with abnormal liver stiffness measurement (LSM) using
transient elastography in RA patients receiving MTX.
Materials and methods
Patients
We consecutively enrolled 150 patients with RA to this
study from October 2011 to January 2012 according to
the initial inclusion criteria as follows: (1) patients diag-
nosed at the Division of Rheumatology, Severance hos-
pital, Yonsei University College of Medicine, with RA
based on the American College of Rheumatology 1987
revised criteria [16]; (2) those who had received MTX
and/or other DMARDs over 24 weeks; (3) those who
had no history of chronic liver diseases, such as viral
hepatitis or structural abnormalities identified in the
10th revised International Classification of Diseases
(ICD-10); (4) those who had never received medication
for liver diseases under the Korean Drug Utilization
Review (DUR) system; and (5) those who gave informed
consent for their participation. The majority of patients
(94.3%) took blood tests on the same day they under-
went LSM and ultrasonography, while six patients had
blood tests up to 2 weeks earlier.
The additional inclusion criteria based on the results of
laboratory tests or LSM and ultrasonography included:
normal ranges of platelet count (> 150,000/mm3), aspartate
aminotransferase (AST) (≤ 40 IU/L), alanine aminotrans-
ferase (ALT) (≤ 40 IU/L), total bilirubin (≤ 1.2 mg/dL),
serum albumin (≥ 3.5 mg/dL), gamma-glutamyltranspepti-
dase (GGT) (≤ 54 IU/L), alkaline phosphatase (ALP)
(≤ 115 IU/L), prothrombin time (≤ 1.16 international nor-
malized ratio [INR]), successful or reliable LSM, and
normal structure on ultrasonography.
Among 150 patients who were recruited, eight (5.3%)
were excluded due to LSM failure (n = 5) or unreliable
LSM (n = 3) (Figure 1). Of those with reliable LSM,
37 patients were further excluded based on our exclusion
criteria described above (Figure 1). Finally, 105 patients
were selected for statistical analysis. This study was
approved by the Institutional Review Board of Severance
Hospital.
Demographic and laboratory findings and medications
On the same day as the LSM, height, weight, waist circum-
ference, and blood pressure were also measured to calcu-
late body mass index (BMI) and determine the prevalence
of metabolic syndrome. Metabolic syndrome was diag-
nosed in subjects showing at least three of the five follow-
ing features: (1) waist circumference > 90 cm in men and
> 80 cm in women according to ethnicity; (2) triglycerides
≥ 150 mg/dl (1.7 mmol/L); (3) high density lipoprotein
(HDL) cholesterol < 40 mg/dl (1.03 mmol/L) in men and
< 50 mg/dl (1.29 mmol/L) in women; (4) blood pressure
≥ 130/85 mmHg and (5) fasting plasma glucose ≥ 110 mg/
dl [17]. The laboratory results (as per the aforementioned
additional inclusion criteria), were obtained on the day of
the LSM. The cumulative doses of medications including
MTX, leflunomide, sulfasalazine, hydroxychloroquine, pre-
dnisolone, meloxicam, and celecoxib were calculated. The
cumulative dose of each medication was defined as the
accumulated area under the curve (AUC) from the time of
drug initiation to the time of LSM during the interval
follow-up days (see Additional file 1).
Liver stiffness measurement and ultrasonography
LSM was performed by a single experienced independent
physician (who had previously performed more than
10,000 examinations) blind to the clinical data of the
study population, according to the examination protocol
Figure 1 Selection of the study population. LSM, liver stiffness
measurement; INR, international normalized ratio.
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described in previous studies [10-12]. The results were
expressed as kilopascals (kPa), and the success rate was
calculated as the number of valid measurements divided
by the total number of measurements. Only LSM exami-
nations with at least 10 validated measurements and a
success rate of at least 60% were considered reliable. The
median value of successful measurements was selected as
the representative LSM value for that subject, when an
interquartile range to median value ratio was less than
0.3. Any LSM that did not satisfy the above conditions
was considered unreliable and was excluded from further
analysis. We also performed ultrasonography to exclude
the patients who had any morphological abnormalities
that might affect the LSM results.
A cutoff value for abnormal LSM
We referred to LSM values which were derived from the
most well-designed Asian study that investigated healthy
living liver and kidney donors in South Korea (with LSM
5th and 95th percentiles 3.9 to 5.3 kPa) and we adopted
5.3 kPa as the cutoff value for abnormal LSM values, indi-
cating the potential development of silent liver fibrosis [10].
Statistical analyses
All statistical analyses were conducted using the SPSS
package for Windows version 11.5 (SPSS Inc., Chicago, IL,
USA). Continuous variables were expressed as mean ± SD
or median (range), as appropriate. Significant differences
between the two groups according to LSM values above
5.3 using the chi square test, and Fisher’s exact test for
categorical data, and the Mann-Whitney test was used for
continuous variables. The correlation between LSM values
and variables was evaluated using univariate Pearson’s cor-
relation. Univariate analysis of association between LSM
values and each variable was performed using linear
regression. The odds ratio (OR) was assessed using multi-
variate logistic regression of variables with P-values less
than 0.05 upon univariate analysis. The optimal cutoff
value of the cumulative dose of leflunomide for the predic-
tion of abnormal LSM values was extrapolated by calculat-
ing the area under the receiver operator characteristic
curve (AUROC), and selection to maximize the sum of sen-
sitivity and specificity. In addition, the OR of the cumula-
tive dose of leflunomide for abnormal LSM values was
analyzed using contingency tables and the chi square test.
P-values < 0.05 were considered statistically significant.
Results
Baseline characteristics and comparison between patients
with and without abnormal LSM values
The baseline characteristics are summarized in Table 1.
The median age of the 105 patients (20 men and 85
women) was 54 years. The median BMI was 22.1 kg/m2,
and six patients (5.7%) had metabolic syndrome. The
median disease duration was 140.4 (range, 26 to 739)
weeks. The median cumulative doses of MTX and lefluno-
mide were 2,032.5 mg and 7,800.0 mg, respectively. The
median LSM value was 4.4 (range, 2.8 to 17.8) kPa.
Twenty four of the 105 patients (22.9%) had abnormal
LSM values and three patients (2.9%) had LSM values
over 8.0 kPa.
Twenty-four of the 105 patients (22.9%) had abnormal
LSM values when patients were classified into two groups
according to the cutoff (5.3 kPa). There were no significant
differences between the two groups in disease duration,
demographic, or laboratory variables, including liver
enzymes. Among medications, the cumulative dose of
leflunomide in patients with abnormal LSM values was
significantly higher than that in patients with normal LSM
values (P = 0.008) (Table 1).
Correlation between LSM and other variables
In the univariate analysis, GGT levels and the cumulative
doses of leflunomide and prednisolone significantly corre-
lated with LSM values (r = 0.249, r = 0.285, and r = 0.362,
P < 0.05 for all), whereas the cumulative dose of MTX
showed no significant correlation with LSM values (P =
0.273) (Additional file 2).
Univariate and multivariate analysis
GGT levels and the cumulative doses of leflunomide and
prednisolone were significantly and positively associated
with LSM values on univariate analysis (b = 0.249, b =
0.285 and b = 0.36, respectively) (Table 2). On multivari-
ate logistic regression of these significant variables, the
cumulative dose of leflunomide was the only predictor of
abnormal LSM values (P = 0.007) (Table 3).
Optimal cutoff for the cumulative dose of leflunomide in
predicting abnormal LSM values
Since the cumulative dose of leflunomide was the only
variable that independently discriminated patients with
abnormal LSM values receiving MTX over 24 weeks, we
calculated the optimal cutoff for the cumulative dose of
leflunomide in predicting abnormal LSM values in 53 RA
patients receiving MTX plus leflunomide, based on ROC
curve analysis. We found that 19,170 mg of the cumula-
tive dose of leflunomide was a strong predictor of abnor-
mal LSM (AUROC 0.735, 95% confidence interval 0.568,
0.903, P = 0.008, sensitivity 60%, specificity 89.5%).
When we classified RA patients receiving MTX and
leflunomide into two groups based on the calculated cutoff
for leflunomide (19,170 mg), 13 of 53 patients were parti-
tioned into the group with a cumulative dose of lefluno-
mide ≥ 19,170 mg. Abnormal LSM values were identified
more frequently in these patients than in those with a
cumulative dose of leflunomide < 19,170 mg (69.2% (9/13
patients) vs. 15.0% (6/40 patients), P < 0.001) (Figure 2).
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Furthermore, patients with a cumulative dose of lefluno-
mide over 19,170 mg had a significantly higher risk of
having abnormal LSM values than those without (OR
12.750, P < 0.001, 95% confidence interval 2.952, 55.067).
Discussion
In clinical practice, if the results of liver-related laboratory
tests are abnormal, the potential liver damage and progres-
sion of fibrosis can easily be spotted by physicians, and the
drug regimen or treatment strategy can be altered. How-
ever, when patients with RA have no evidence of underly-
ing chronic liver disease and have persistently normal
liver-related laboratory results, the silent progression of
liver fibrosis can be missed. Indeed, data are scarce on the
prevalence of silent liver fibrosis, and on how to monitor
or detect this adverse outcome due to long-term use of
DMARDs by patients with RA and normal liver function.
Furthermore, no significant relationship between Roenigk
Table 1 Baseline characteristics in RA patients who were receiving MTX and comparison between patients with and
without abnormal liver stiffness measurement (LSM)
All patients (n = 105) LSM < 5.3 kPa(n = 81) LSM > 5.3 kPa(n = 24) P-value
Demographic variables
Age, years 54.0 (25, 73) 52.5 ± 10.3 52.3 ± 11.8 0.852
Male gender 20 (19.0) 16 (19.8) 4 (16.7) 0.736
Body mass index, kg/m2 22.1 (18.1, 27.6) 22.1 ± 2.5 22.3 ± 2.4 0.723
Metabolic syndrome, number patients (%) 6 (5.7) 3 (3.7) 3 (12.5) 0.105
Disease duration, weeks 140.4 (26.1, 739.2) 171.8 ± 123.9 240.5 ± 159 0.059
Laboratory variables
C-reactive protein, mg/L 1.2 (0, 124.0) 3.1 ± 5.7 6.9 ± 25.1 0.766
Erythrocyte sedimentation rate, mm/hr 33.0 (2, 111) 37.3 ± 22.3 32.4 ± 20.7 0.362
White blood cells, count/mm3 5,960.0 (2,390.0, 12,870.0) 6,355.9 ± 2,009.0 5,801.7 ± 1,853.9 0.319
Hemoglobin, g/dL 12.7 (9.9, 16.2) 12.7 ± 1.1 13.0 ± 1.0 0.324
Platelet count, × 1,000/mm3 241.0 (134.0, 470.0) 253.0 ± 60.3 250.8 ± 69.0 0.723
Prothrombin time, INR 0.9 (0.8, 1.2) 1.0 ± 0.1 1.0 ± 0.1 0.726
Glucose, mg/dL 85.0 (70.0, 125.0) 87.4 ± 10.7 86.4 ± 5.0 0.652
Blood urea nitrogen, mg/dL 14.4 (0.9, 28.1) 15.2 ± 4.8 14.1 ± 4.6 0.249
Creatinine mg/dL 0.7 (0.5, 1.3) 0.7 ± 0.2 0.7 ± 0.1 0.858
Uric acid, mg/dL 3.8 (1.5, 8.9) 4.0 ± 1.2 4.1 ± 1.8 0.582
Aspartate aminotransferase, IU/L 21.0 (13.0, 34.0) 21.9 ± 5.5 22.4 ± 6.8 0.881
Alanine aminotransferase, IU/L 17.0 (8.0, 39.0) 18.9 ± 7.7 19.0 ± 7.7 0.879
Total protein, mg/dL 6.9 (5.5, 7.9) 7.0 ± 0.4 7.0 ± 0.5 0.730
Serum albumin, mg/dL 4.3 (3.5, 4.9) 4.3 ± 0.3 4.2 ± 0.4 0.815
Total bilirubin, mg/dL 0.6 (0.2, 1.1) 0.6 ± 0.2 0.6 ± 0.2 0.461
Alkaline phosphatase, IU/L 52.0 (38.0, 110.0) 56.4 ± 17.0 54.7 ± 13.1 0.976
Gamma-glutamyltranspeptidase, IU/L 17.0 (5.0, 53.0) 22.6 ± 15.1 26.3 ± 19.1 0.340
Triglyceride, mg/dL 90.0 (26.0, 269.0) 108.9 ± 55.4 92.2 ± 41.4 0.197
High density cholesterol, mg/dL 55.0 (19.0, 86.0) 55.9 ± 10.4 53.2 ± 19.1 0.772
Low density cholesterol, mg/dL 105.4 (52.8, 172.6) 108.8 ± 26.8 107.4 ± 26.8 0.743
Cumulative dose of medication, mg
Methotrexate (105 patients) 2,032.5 (285.0, 7,800.0) 2,334.0 ± 1,939.9 3,127.9 ± 2,072.7 0.086
Leflunomide (53 patients) 7,800.0 (280.0, 38,520.0) 9,291.1 ± 9,331.8 19,919.3 ± 12,716.8 0.008
Sulfasalazine (82 patients) 360,000.0 (30,000.0, 6,028,000.0) 727,778.7 ± 969,150.7 1,093,547.6 ± 1,330,930.2 0.111
Hydroxychloroquine (65 patients) 94,600.0 (4,200.0, 868,000.0) 115,248.0 ± 120,975.1 182,013.3 ± 208,807.9 0.129
Prednisolone (89 patients) 3,015.0 (372.5, 20,212.5) 4,642.1.0 ± 4,196.7 6,756.7.1 ± 6,156.5 0.472
Meloxicam (90 patients) 6,273.8 (210.0, 2,895,000.0) 90,205.0 ± 363,930.2 161,274.6 ± 644,791.4 0.793
Celecoxib (70 patients) 163,000.0 (1,000.0, 1,503,000.0) 218,505.7 ± 253,487.6 316,705.9 ± 313,982.7 0.239
LSM
LSM, kPa, median (range) 4.4 (2.8, 17.8) NA NA NA
LSM, kPa, median (IQR) 0.14 (0.02, 0.29) NA NA NA
Success rate, %, median (IQR) 100.0 (63.0, 100.0) NA NA NA
Values are expressed as median (range, IQR), number (%), or mean ± SD. INR, international normalized ratio; NA: not applicable.
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grading of liver fibrosis and quantitative results of liver-
related laboratory tests was identified in a previous study
of liver biopsies performed in 16 patients with RA and
long-term use of MTX [18]. Thus, in this cross-sectional
study, we focused only on patients with RA who were not
suspected of having underlying chronic liver disease, and
found that leflunomide combined with MTX had a signifi-
cant correlation with silent liver fibrosis.
So far, in addition to age, alcohol consumption, duration
of RA, serum albumin level, obesity, and pre-existing pul-
monary fibrosis, the cumulative dose and duration of
MTX use have been reported as risk factors for histologi-
cal fibrosis or cirrhosis in patients with RA receiving MTX
[19-21]. Therefore, concerns related to hepatotoxicity of
MTX, including elevated liver enzymes or progression of
fibrosis, has limited physicians’ use of MTX in RA patients
Table 2 Univariate analysis of association between liver stiffness measurement (LSM) and other variables
Beta 95% Confidentialinterval P-value
Demographic variables
Age, years - 0.145 - 0.054, 0.008 0.140
Body mass index, kg/m2 0.134 - 0.041, 0.227 0.173
Disease duration, weeks 0.090 - 0.001, 0.004 0.362
Laboratory variables
C-reactive protein, mg/L 0.051 - 0.019, 0.032 0.608
Erythrocyte sedimentation rate, mm/hr - 0.147 - 0.026, 0.004 0.135
White blood cell, count/mm3 - 0.071 0.000, 0.000 0.473
Hemoglobin, g/dL 0.050 - 0.232, 0.391 0.612
Platelet count, × 1,000/mm3 - 0.044 - 0.007, 0.004 0.654
Prothrombin time, INR - 0.056 - 6.729, 3.738 0.572
Glucose, mg/dL 0.001 - 0.034, 0.034 0.995
Blood urea nitrogen, mg/dL - 0.045 - 0.085, 0.053 0.651
Creatinine, mg/dL - 0.061 - 2.605, 1.358 0.534
Uric acid. mg/dL 0.148 - 0.058, 0.438 0.132
Aspartate aminotransferase, IU/L 0.146 - 0.014, 0.099 0.136
Alanine aminotransferase, IU/L 0.131 - 0.014, 0.071 0.183
Total protein, mg/dL 0.002 - 0.807, 0.822 0.985
Serum albumin, mg/dL 0.089 - 0.645, 1.741 0.364
Total bilirubin, mg/dL - 0.048 - 2.135, 1.299 0.630
Alkaline phosphatase, IU/L - 0.372 - 0.024, 0.017 0.711
Gamma-glutamyltranspeptidase, IU/L 0.249 0.008, 0.058 0.010
Triglyceride, mg/dL - 0.033 - 0.007, 0.005 0.738
High density cholesterol, mg/dL - 0.185 - 0.050, - 0.001 0.059
Low density cholesterol, mg/dL - 0.161 - 0.022, 0.002 0.101
Cumulative dose of medication, mg
Methotrexate (105 patients) 0.108 0.000, 0.000 0.273
Leflunomide (53 patients) 0.285 0.000, 0.000 0.038
Sulfasalazine (82 patients) 0.031 0.000, 0.000 0.782
Hydroxychloroquine (65 patients) 0.072 0.000, 0.000 0.567
Prednisolone (89 patients) 0.362 0.000, 0.000 < 0.001
Meloxicam (90 patients) - 0.012 0.000, 0.000 0.909
Celecoxib (70 patients) 0.182 0.000, 0.000 0.131
INR, international normalized ratio.
Table 3 Multivariate analysis of independent prediction of silent liver fibrosis
Odds ratio 95% Confidentialinterval P-value
Laboratory variables
Gamma-glutamyltranspeptidase, IU/L 1.009 0.953, 1.068 0.757
Cumulative dose of medications, mg
Leflunomide (53 patients) 1.000 1.000, 1.000 0.007
Prednisolone (89 patients) 1.000 1.000, 1.000 0.547
Lee et al. Arthritis Research & Therapy 2012, 14:R232
http://arthritis-research.com/content/14/5/R232
Page 5 of 8
with viral hepatitis or liver cirrhosis [22]. Despite these
reports, in this study, we found that the cumulative dose
of MTX did not significantly correlate with LSM values,
and was statistically equivalent between patients with nor-
mal and abnormal LSM values, similar to the results of
previous studies [13,14]. Further, when we stratified our
study population into two groups based on a previously
proposed cutoff MTX cumulative dose of 4,000 mg [13],
the proportion of patients with abnormal LSM values was
equivalent between the groups (P = 0.572). Also, when we
reanalyzed 52 RA patients receiving MTX but not lefluno-
mide, we found that 9 patients (17.3%) had abnormal LSM
values and there were no significant differences between
patients with and without abnormal LSM values. However,
these results did not suggest that the cumulative dose of
MTX may not be related to silent liver fibrosis in RA
patients. Our study design, based on the study of patients
with normal liver function, without underlying chronic
liver disease, and who had been exposed to MTX for more
than 24 weeks, might have reduced the extent of the effect
of MTX. To clarify this, a further study will be necessary,
including RA patients regardless of the administration of
MTX.
Meanwhile, leflunomide has been reported to increase
the frequency of abnormal liver enzyme up to 19% [23].
The currently recommended monitoring guidelines sug-
gest leflunomide dose reduction or discontinuation
when ALT levels are more than two to three times the
normal level [24]. However, no reports are available that
propose practical guidelines for monitoring leflunomide
hepatotoxicity in RA patients with normal liver function.
In our study, we found that the cumulative dose of leflu-
nomide correlated closely with LSM values, and could be
used as an independent predictor for abnormal LSM
values. We selected 53 patients (51%) who received both
leflunomide and MTX, and obtained the cutoff for the
leflunomide cumulative dose of 19,170 mg (5.3 years with
10 mg tablets or 2.6 years with 20 mg tablets), because in
Korea, leflunomide is usually administered with MTX
[25]. Patients with a cumulative dose of leflunomide over
19,170 mg had a significantly higher risk of having an
abnormal LSM value than those with less than 19,170
mg; the hazard ratio was 12.75. On the other hand, when
we divided patients into two groups according to the pre-
sence of leflunomide and compared LSM values between
the two groups, patients receiving MTX plus leflunomide
(n = 53) had higher LSM values than those receiving
MTX only (n = 52) (5.0 ± 2.2 vs 4.3 ± 0.9, P = 0.035).
However, we found no significant difference in the fre-
quency of abnormal LSM values according to the pre-
sence of leflunomide (P = 0.134). Thus, in RA patients
receiving MTX and a cumulative dose of leflunomide
over 19,170 mg (rather than the fact of its administra-
tion), we suggest that transient elastography be per-
formed to for check silent liver fibrosis, even if the
patient has normal liver function.
In our study, silent liver fibrosis was assessed using
noninvasive transient elastography, instead of invasive
liver biopsy. We defined 5.3 kPa as the cutoff for abnor-
mal LSM values, which was adopted from a previous
study that investigated the normal range of LSM values
in healthy living liver and kidney donors in South Korea
(5th - 95th percentiles for LSM 3.9 to 5.3 kPa) [10].
Although our patients had normal liver function and
were without chronic liver disease, their range of LSM
values seemed slightly higher (5th to 95th percentiles 3.2
to 6.7 kPa) than healthy Koreans, potentially because of
long-term use of DMARDs. A value of 5.3 kPa in our
study seems relatively low to predict the presence of
clinically significant liver fibrosis. However, this strict
cutoff may draw physicians’ attention to silent liver
fibrosis in patients with RA receiving MTX and lefluno-
mide, and encourage the adjustment of hepatotoxic
medication doses to prevent irreversible liver fibrosis.
Our study has several issues. First, the lack of histologi-
cal data is the main limitation, especially in patients with
abnormal LSM values. Second, the cutoff LSM value of 5.3
kPa is not high enough to analyze the prevalence of clini-
cally significant fibrosis [26]. Further study with higher
prevalence of high LSM values can overcome this issue.
Third, because this study was cross-sectional, baseline
LSM values prior to the initiation of DMARDs were not
available. Finally, serial measurements of LSM for moni-
toring changes in the fibrotic burden were not available, in
Figure 2 The prevalence of abnormal liver stiffness
measurement (LSM) values among patients with rheumatoid
arthritis receiving methotrexate with a cumulative dose of
leflunomide over 19,170 mg. Abnormal LSM values were more
frequently identified in patients with cumulative doses of
leflunomide ≥ 19,170 mg than in those with cumulative doses of
leflunomide < 19,170 mg (69.2% (9/13 patients) vs. 15.0% (6/40
patients), P < 0.001).
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spite of its noninvasiveness. If future studies can serially
measure LSM, they might reveal a dynamic correlation
between LSM and differing doses of DMARDs, including
MTX and leflunomide.
Conclusions
In this study, the cumulative dose of leflunomide corre-
lated closely with the presence of silent liver fibrosis,
reflected by abnormal LSM values, and it was the only
independent predictor of abnormal LSM in patients with
RA, who had received MTX over 24 weeks. However,
further studies are required to investigate whether treat-
ment regimens or strategies should be modified when
abnormal LSM values are identified.
Additional material
Additional file 1: The definition of the cumulative dose of each
medication. Figure showing the cumulative dose of each medication,
which was defined as the accumulated area under the curve (AUC) from
the time of drug initiation to the time of liver stiffness measurement
(LSM) during interval follow-up days.
Additional file 2: Correlation between liver stiffness measurement
(LSM) values and other variables. Table showing gamma-GT levels and
the cumulative doses of leflunomide and prednisolone significantly
correlated with LSM; the cumulative dose of methotrexate showed no
significant correlation with LSM.
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